N/A N=18 Imaging Biomarkers of Lymphatic Dysfunction
Secondary Lymphedema
Primary: Assessing a Change in Bioimpedance Spectroscopy (BIS) — 1.3; 1.8 Change of score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=82 Acupuncture for Chronic Lymphedema
Breast Cancer With Chronic Lymphedema
Primary: Lymphedema as Measured at Baseline and at 6 Weeks — 4.74; 4.82; 4.29; 4.76 cm
N/A N=80 A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection
Lymph Node Dissection · Lymphoedema · Lymphocoele
Primary: Postoperative Draining Time — 31; 32 days
N/A N=1 Prospective Evaluation of a Surgical Solution for Breast Cancer-Associated Lymphedema
Lymphedema · Edema
Primary: Change in Limb Volume — -15; -202 mL
N/A N=75 Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status
Lymphedema · Breast Cancer
Primary: Number of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy — 19; 21; 22 participants
N/A N=568 Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection
Lymphedema
Primary: Number of Participants Who Were Lymphedema-free 18 Months After Randomization — 114; 135 Participants
N/A N=28 Treatment of Breast Cancer-related Lymphedema With a Negative Pressure Device
Lymphedema, Secondary · Lymphedema of Upper Limb
Primary: Recruitment Rates — 32.5; 37.5 rate of recruitment
Phase 4 N=50 Low Level Laser Treatment and Breast Cancer Related Lymphedema
Lymphedema
Primary: LDex Change- — 28.0; 17.8; 22.2 LDex
N/A N=13 Upper Extremity Lymphatic Mapping for Breast Cancer Patients
Breast Cancer · Axillary Lymph Node Dissection
Primary: Number and Prevalence of Metastases of Blue Nodes in the ALND Specimen (Nodes Draining the Breast). — 0 participants
Phase 4 N=50 Lymphedema Study for Arm or Leg Lymphedema
Lymphedema
Primary: Part 1: Count of Participants Able to Complete Ketoprofen Treatment — 50 Participants
Phase 2 N=11 Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related Lymphedema
Head and Neck Neoplasms · Head and Neck Lymphedema · Head and Neck Cancer
Primary: Lymph Movement Measured by ICG Lymphography. — 5; 5; 0; 0 Participants
Phase 2 N=10 A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer
Lymphedema
Primary: Change in Volume Ipsilateral Lymphedema in Arm — -161.0; -372.8 mL — p=0.0658
N/A N=21 LLLT Combined With CDT in Breast Cancer-Related Lymphedema
Breast Cancer · Lymphedema
Primary: Arm Volume — 1.48; 1.58 cm^3
N/A N=194 Effectiveness of Fluoroscopy-guided MLD for Treatment of BCRL
Breast Neoplasm · Lymphedema
Primary: Lymphoedema Volume at the Level of the Arm/ Hand — 1.228; 1.249; 1.218; 1.175 Inter-limb ratio
N/A N=52 Effect of Intermittent Pneumatic Compression on Ulcer Healing in Subjects With Secondary Lymphedema
Lymphedema
Primary: Median Time to Wound Closure at 9 Months — 141; 211 median number of days for complete heali
N/A N=24 Study to Evaluate the Safety and Effectiveness of Dayspring for Lower Extremity Lymphedema
Lymphedema · Lymphedema Lower Extremity · Chronic Venous Insufficiency
Primary: LYMQOL (LYMphedema Quality of Life) ***All Relevant Time Points Used in the Calculation in the Time Frame (e.g., Baseline and 3 Months).*** — .83 units on a scale
N/A N=36 Intermittent Pneumatic Compression in Women With Lipo-lymphedema (Lipedema With Swelling)
Lipedema · Lipolymphedema
Primary: Change in Circumferential Measurements Over Time — -0.5; -1.0; -1.3; -2.0 cm
N/A N=25 Low-Level Laser in Head and Neck Chronic Lymphedema
Head and Neck Cancer · Lymphedema · Fibrosis
Primary: Total Severity of External Lymphedema and Fibrosis (LEF) — 5.42; 4.08; 3.22; 4.62 score on a scale
N/A N=12 Low-Level Laser in Treatment of Head and Neck Lymphedema: A Pilot Study
Head and Neck Cancer · Lymphedema · Fibrosis
Primary: Number of Participants Consented and Enrolled in Study — 12 Participants
Phase 4 N=74 Post-Operative Drainage Following Lymph Node Dissection
Malignant Melanoma · Carcinoma, Squamous Cell
Primary: Post-operative Wound Drainage. — 892.5; 762.5; 565; 590 ml — p=0.704
N/A N=9 Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)
Breast Cancer · Upper Extremity Lymphedema
Primary: Volume Changes as Measured by Perometry
N/A N=236 A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema
Lymphedema · Lymphedema of Face · Lymphedema, Secondary
Primary: Internal Lymphedema - Endoscopy — -0.12; -0.06; -0.21; -0.16 Score on a scale
N/A N=43 Patient Anxiety Associated With Lymphedema Surveillance Method
Anxiety
Primary: Anxiety — 7.1; 8.8 units on a scale
N/A N=72 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India
Lymphatic Filariasis
Primary: Dermatology Life Quality Index (DLQI) Domain Scores — 3; 0; 1; 0 units on a scale
N/A N=32 Fibrin Glue in Inguinal Lymphadenectomy
Seroma
Primary: Number of Participants With Seroma Formation — 2; 8 participants — p=0.022
Phase 2 N=20 Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid
Eyelid Sebaceous Gland Carcinoma
Primary: Sentinel Lymph Node Positivity — 2 Participants
N/A N=21 Treatment Response to Different Lymphoedema Compression Programs Using a Pneumatic Compression Device
Lower Extremity Lymphoedema · Leg Lymphoedema
Primary: Limb Volume (ml) — -197; -60; 45 ml
N/A N=59 Self-Care for Head and Neck Cancer Survivors With Lymphedema and Fibrosis
Head and Neck Cancer · Lymphedema · Fibrosis
Primary: Feasibility of the LEF-SCP (Self-Care Skill Training Sessions) — 20; 18 Participants
N/A N=35 Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema
Breast Cancer · Head and Neck Cancer · Lymphedema
Primary: Change From Baseline in Patient-specified and Reported Symptoms on the Measure Yourself Medical Outcome Profile (MYMOP) — 1.51 units on a scale — p=<0.001
N/A N=934 Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases
Breast Cancer
Primary: 5-year Disease-Free Survival — 84.4; 87.8 percentage of participants — p=0.004